Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide with Dexamethasone and Cyclophosphamide in Relapsed/Refractory Myeloma
NCT01432600Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2011
- Primary completion
- Aug 2016
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pomalidomide in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 Days and Overall Response Rate at 36 Months. Started Nov 2011; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01432600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01432600.